Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Lions Health 2017: Health & Wellness Winners

The Health & Wellness winners were revealed at the Lions Health 2017 Awards Show.

Read More »

FCB’s Area 23 Named “Healthcare Agency of the Year” at 2017 Cannes Lions Health Festival

Area 23, an FCB Health company, was named “Healthcare Agency of the Year” during the 2017 Cannes Lions Health award ceremonies.

Read More »

Exercise may stave off postpartum depression

Physical activity during and after pregnancy improves psychological wellbeing and may protect against postpartum depression, according to a new analysis.

Read More »

Sanofi chief says U.S. Supreme Court ruling on biologics has “immediate impact”

The U.S Supreme Court decision to speed access to copycat biologics drugs was expected but has an “immediate impact,” Sanofi’s chief executive told Reuters.

Read More »

New Data Reveals This New York Biotech’s Pipeline Could be a Game Changer

TG Therapeutics has had no shortage of positive data as it has seen strong results from its Phase III anti-CD20 monoclonal antibody TG-1101 and its triple combination treatment of TGR-1202, TG-1101 and ibrutinib (Imbruvia).

Read More »

Sonar Products, Stratus Pharma Ordered to Cease Operations

A federal judge ordered Florida-based Stratus Pharmaceuticals and New Jersey-based Sonar Products to cease the manufacturing and distribution of drugs that are unapproved, mislabeled or contaminated.

Read More »

New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis Presented at EULAR 2017

Eli Lilly and Company and Incyte Corporation announced a new pooled analysis of data from eight Olumiant (baricitinib) clinical trials, showing that baricitinib-treated and placebo-treated patients with moderate-to-severe rheumatoid arthritis had similar rates of serious infection incidents.

Read More »

J&J Completes Acquisition of Actelion

Johnson & Johnson today announced the completion of the acquisition of Actelion Ltd. for a total purchase price of approximately $30 billion in cash.

Read More »

Adamis wins U.S. approval to sell EpiPen rival

Adamis Pharmaceuticals Corp. received U.S. approval for its emergency epinephrine syringes to treat severe allergic reactions that the company intends to be a lower cost rival to Mylan NV’s widely used EpiPen, sending its shares up more than 50 percent.

Read More »

FDA Voice Blog: Fostering Medical Innovation – A Plan for Digital Health Devices

“FDA will soon be putting forward a broad initiative that is focused on fostering new innovation across our medical product centers,” according to Scott Gottlieb, M.D. Commissioner of the U.S. Food and Drug Administration. “I will have more to say on many elements of this initiative soon. However, today I want to focus on one critical aspect of this innovation initiative: A new Digital Health Innovation Plan that is focused on fostering innovation at the intersection of medicine and digital health technology. This plan will include a novel, post-market approach to how we intend to regulate these digital medical devices.”

Read More »

UK will pay for Roche breast cancer drug

A breast cancer drug at the center of a prolonged pricing row in Britain will now be paid for routinely following a discount deal between Roche and the NHS.

Read More »

EULAR 2017: Lilly’s Taltz (ixekizumab) Demonstrated Significant Improvements in Disease Signs and Symptoms at 24 Weeks Among Patients with Active Psoriatic Arthritis Who Had Prior Inadequate Response or Intolerance to TNF Inhibitors

Eli Lilly and Company announced that patients with active psoriatic arthritis who had inadequate response to one or two TNF inhibitors or were intolerant of TNF inhibitors treated with Taltz (ixekizumab) achieved significant improvement in signs and symptoms of their disease at 24 weeks when compared to placebo.

Read More »

Senate may keep some Obamacare taxes in U.S. healthcare overhaul

Republican senators trying to repeal Obamacare are forming consensus to keep some of the U.S. healthcare law’s taxes they long criticized, in hopes of delaying more drastic funding cuts, particularly to the Medicaid program for the poor and disabled.

Read More »

Disappointing Phase II Data for Epizyme drug

Tazemetostat – an experimental Phase II treatment for lymphomas – showed a 29 percent overall response rate in patients with DLBCL, below investors’ expectations.

Read More »

New Biotech Incubator Opened Up in the Big Apple – With Room for 25 Startups

Startup biotech companies have a new place to call home in downtown Manhattan thanks to Alexandria Real Estate Equities.

Read More »

In-case, any of the aspects is missing, your regulation article could neglect to meet

NPEC is among the essay contest scholarships that’s certainly available to senior high school pupils. One scholarship specially is an essay contest. If you’re trying to find scholarship essay competitions are discounts confident you go through everything which is supplied about the contest, by way of example, qualification criteria along with the required output. […]

Read More »

Google backs new European biotech drug fund

Google is betting on the potential of European biotech companies to deliver life-changing drugs by investing alongside Swiss company Novartis in a new $300 million fund run by leading life sciences investment firm Medicxi.

Read More »

Janssen Presents Long Term Phase 3 Efficacy and Safety Data of Sirukumab in Rheumatoid Arthritis Patients Who had an Inadequate Response and/or Who Were Intolerant to Anti-TNFs

Janssen-Cilag International NV today announced long-term results from SIRROUND-T, a pivotal Phase 3 study that showed sirukumab improved the signs and symptoms of moderately to severely active rheumatoid arthritis (RA) through 52 weeks of treatment in adult patients with an inadequate response and/or intolerance to anti-tumor necrosis factor (TNF)-alpha treatments.

Read More »

J&J’s flu drug succeeds in mid-stage trial

J&J said its experimental flu drug significantly reduced the presence of the virus in patients with a type of influenza in a mid-stage study.

Read More »

Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of adalimumab biosimilar candidate to Humira

Boehringer Ingelheim announced results from the pivotal Phase III VOLTAIRE-RA1 study, confirming that its adalimumab biosimilar candidate BI 695501 and Humira have similar efficacy, safety and immunogenicity in patients with moderately-to-severely active rheumatoid arthritis.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom